|
|
|
Pharmaceutical Manufacturing and Packing Sourcer
|
Our everyday lives are becoming dependent on smart phones and ‘cloud’ technologies. My sons (both in their early 20s) are constantly on their iPhones, trawling social media, gaming or taking ‘selfies’. Ironically, mobile phones are used more for managing our lives than for audible communication. On them, we can book flights and remotely change the central heating setting in our homes. This is the age we now live in, whether we like it or not. The ‘Internet of Things’ (IoT) is infiltrating every facet of our personal and working lives. Even the pharmaceutical industry – historically very conservative in its practices and slow to change – is moving with the times.
In this edition, Eva Weber at ABBYY Europe gives a vision of the factory of the future, where she predicts we will see greater integration of robotics with optical recognition systems throughout the manufacturing chain (page 22). Jeff Hackney and Mike Boudreaux at Emerson also describe how the IoT is influencing practices relating to data management within the healthcare industries – both in the production sectors and for the design of medical devices (page 61).
Data integrity is vitally important within pharma. Articles from Piritta Maunu at Vaisala (page 18) and Léon van Deurse at Chemgineering (page 40) provide insights into the current practices for ensuring IT security and information integrity for computerised systems, introducing the soon-to-become-familiar acronyms of GAMP 5, ITIL and COBIT.
|
Read full article from PDF >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
 |
News and Press Releases |
 |
Mogrify enters research collaboration with the MRC Laboratory of Molecular Biology
Cambridge, UK, 11 January 2021: Mogrify Limited (Mogrify®), a UK company aiming to transform the development of ex vivo cell therapies and pioneer the field of in vivo reprogramming therapies, and the MRC Laboratory of Molecular Biology (LMB), a world-class research laboratory dedicated to understanding important biological processes at the molecular level, today announced an exploratory research collaboration. The project aims to develop novel protein expression systems by leveraging recent advances in direct cell reprogramming to help improve the production of proteins which are not produced sufficiently well in existing expression systems.
More info >> |
|
 |
White Papers |
 |
|
eSource: Reducing Site Workload for Better, Faster, Safer Clinical Trials
Clinical Ink
Unlike traditional electronic data capture (EDC),
SureSource, Clinical Ink’s eSource platform, was designed from the
beginning to minimize clinical trial complexity for site users. A Site Impact Survey provides
scientific evidence regarding the impact of SureSource from 517 site
users. Results confirm it significantly reduces workload, lessens
queries, and improves data quality compared to paper and EDC. In this
white paper, we quantitatively evaluate survey outcomes, provide
qualitative feedback from survey respondents, and highlight the observed
benefits of SureSource for transforming clinical research.
More info >> |
|
|
